IV. SBRT Clinical Treatment Programs
Pancreatic cancer is a devastating disease with few effective treatment modalities. Recent technological
advances have made possible the delivery of single-fraction stereotactic body radiotherapy
(SBRT) to patients with locally advanced pancreatic tumors. This paper presents experience at Stanford
University with SBRT for patients with unresectable pancreatic cancer. Pancreatic tumors of up
to 100 cm3 could be treated. Patients achieved greater than 90% local control for the remainder of
their lives. Currently, the standard dose for pancreatic tumors treated at this institution is 25 Gy given
in a single fraction. Four-dimensional CT and PET scans have been essential for optimal treatment
planning. PET-CT scanning may be a more effective method for evaluating tumor response than
conventional CT scanning. Adjuvant systemic therapies could be administered in coordination with
SBRT. SBRT is an effective method of treating patients resulting in excellent local control. Current research
is aimed at defining the optimal method of combining this treatment with other cancer
Copyright / Drug Dosage
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.